Literature DB >> 19178774

Relaxing effects of Valeriana officinalis extracts on isolated human non-pregnant uterine muscle.

Francesco Occhiuto1, Annalisa Pino, Dora Rita Palumbo, Stefania Samperi, Rita De Pasquale, Emanuele Sturlese, Clara Circosta.   

Abstract

OBJECTIVES: This study investigated the relaxing effects of Valeriana officinalis L. (Valerianaceae) on human uterine muscle. The major uses of this species in Europe are as a sedative and an anxiolytic; it is also used as a spasmolytic to treat gastrointestinal spasm.
METHODS: We evaluated two valerian extracts (ethanolic and aqueous) in comparison with a natural mixture of valepotriates and nifedipine on spontaneous and agonist-induced contractions in non-pregnant human myometrium in vitro. Qualitative and quantitative chemical analysis was used to correlate the chemical composition of extracts with their spasmolytic effects. Myometrial strips were obtained from hysterectomy specimens of premenopausal women. Longitudinal muscle strips were mounted vertically in tissue baths under physiological conditions to record their isometric contraction. The responses of cumulative concentrations of valerian extracts on spontaneous contractions in the presence and absence of the beta-adrenoceptor blocker atenolol or the cyclooxygenase inhibitor indometacin, and on agonist-induced contractions, were investigated. KEY
FINDINGS: Valerian extracts and valepotriates inhibited uterine contractility in a concentration-dependent manner. Pretreatment with either atenolol or indometacin did not affect the uterine responses to valerian extracts. Valerian extract reduced the maximal contractile response induced by acetylcholine, phenylephrine and histamine independent of the stimulus.
CONCLUSIONS: Valerian extracts may have direct inhibitory effects on the contractility of the human uterus and this justifies the traditional use of this plant in the treatment of uterine cramping associated with dysmenorrhoea.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19178774     DOI: 10.1211/jpp/61.02.0016

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  7 in total

Review 1.  Awareness and current knowledge of epilepsy.

Authors:  Asmat Ullah Khan; Muhammad Akram; Muhammad Daniyal; Naheed Akhter; Muhammad Riaz; Naheed Akhtar; Mohammad Ali Shariati; Fozia Anjum; Samreen Gul Khan; Abida Parveen; Saeed Ahmad
Journal:  Metab Brain Dis       Date:  2019-10-11       Impact factor: 3.584

Review 2.  Nifedipine for primary dysmenorrhoea.

Authors:  Rachel A Earl; Rosalie M Grivell
Journal:  Cochrane Database Syst Rev       Date:  2021-12-18

3.  Aqueous and Ethanolic Valeriana officinalis Extracts Change the Binding of Ligands to Glutamate Receptors.

Authors:  Lisa M Del Valle-Mojica; José M Cordero-Hernández; Giselle González-Medina; Igmeris Ramos-Vélez; Nairimer Berríos-Cartagena; Bianca A Torres-Hernández; José G Ortíz
Journal:  Evid Based Complement Alternat Med       Date:  2010-12-02       Impact factor: 2.629

Review 4.  Botanicals and Their Bioactive Phytochemicals for Women's Health.

Authors:  Birgit M Dietz; Atieh Hajirahimkhan; Tareisha L Dunlap; Judy L Bolton
Journal:  Pharmacol Rev       Date:  2016-10       Impact factor: 25.468

5.  The Effect of Melissa Officinalis Extract on the Severity of Primary Dysmenorrha.

Authors:  Parvaneh Mirabi; Mahshid Namdari; SeidehHanieh Alamolhoda; Faraz Mojab
Journal:  Iran J Pharm Res       Date:  2017       Impact factor: 1.696

6.  Skeletal muscle relaxant effect of a standardized extract of Valeriana officinalis L. after acute administration in mice.

Authors:  Dorian Caudal; Isabelle Guinobert; Aude Lafoux; Valérie Bardot; César Cotte; Isabelle Ripoche; Pierre Chalard; Corinne Huchet
Journal:  J Tradit Complement Med       Date:  2017-10-12

Review 7.  A Nutraceutical Approach to Menopausal Complaints.

Authors:  Pasquale De Franciscis; Nicola Colacurci; Gaetano Riemma; Anna Conte; Erika Pittana; Maurizio Guida; Antonio Schiattarella
Journal:  Medicina (Kaunas)       Date:  2019-08-28       Impact factor: 2.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.